GSK, Ionis claim study success for RNA-based hepatitis B drug [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
GSK and Ionis Pharmaceuticals said their experimental hepatitis B medicine succeeded in two Phase 3 trials, offering patients what might be a “functional cure” for the disease. In releases issued Wednesday, the companies didn't provide details on the effects seen in the B-Well 1 and B-Well 2 studies. The drug, bepirovirsen, met the primary endpoint in both trials and “demonstrated a statistically significant and clinically meaningful functional cure rate,” the companies said. Global regulatory filings are planned for the first quarter of this year based on the data, the companies said. Researchers plan to release the full results at a future medical meeting and in a peer-reviewed journal. Health officials estimate that more than 2 billion people around the world have been infected with the hepatitis B virus and almost 300 million of those patients have developed chronic infections that can lead to cirrhosis and liver cancer. Infants exposed to the virus are especially at risk ,
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readoutsBusiness Wire
- GSK Reports 'Positive' Phase 3 Results From Chronic Hepatitis B Studies [Yahoo! Finance]Yahoo! Finance
- Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis BBusiness Wire
- Ionis to present at 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Ionis Pharmaceuticals (NASDAQ:IONS) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.MarketBeat
IONS
Earnings
- 10/29/25 - Beat
IONS
Sec Filings
- 1/12/26 - Form 8-K
- 1/9/26 - Form 4
- 1/7/26 - Form SCHEDULE
- IONS's page on the SEC website